Diana Mummert
Psychiatry · Fort Worth, TXNPI 1295907764
Payments from drug & device makers
Across 431 payments — averaging $14.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$747
- Sunovion Pharmaceuticals Inc.$404
- Lundbeck LLC$402
- Johnson & Johnson$324
- plus $2K from 27 others
What the payments were for
- Food & beverage$6,083100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 102 | $1,456 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 104 | $1,234 |
| Otsuka America Pharmaceutical, Inc. | 42 | $747 |
| Sunovion Pharmaceuticals Inc. | 50 | $404 |
| Lundbeck LLC | 24 | $402 |
| Johnson & Johnson | 19 | $324 |
| Tris Pharma Inc | 15 | $245 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $163 |
| Eisai Inc. | 8 | $144 |
| Corium, LLC | 9 | $113 |
| Jazz Pharmaceuticals Inc. | 5 | $97 |
| Alkermes, Inc. | 5 | $96 |
| Supernus Pharmaceuticals, Inc. | 5 | $82 |
| Neos Therapeutics, LP | 4 | $81 |
| Noven Therapeutics, LLC | 3 | $72 |
| Vanda Pharmaceuticals Inc. | 3 | $62 |
| Axsome Therapeutics, Inc. | 3 | $58 |
| Adlon Therapeutics L.p. | 4 | $57 |
| Genentech USA, Inc. | 2 | $33 |
| Ironshore Pharmaceuticals Inc. | 1 | $27 |
| Amgen | 1 | $21 |
| Lilly USA, LLC | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Orexo US, Inc. | 1 | $16 |
| Medtronic | 1 | $15 |
| Seqirus USA Inc | 1 | $14 |
| Bausch Health US, LLC | 1 | $14 |
| Almatica Pharma LLC | 1 | $14 |
| Merck | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| OWP Pharmaceuticals, Inc. | 1 | $13 |
| Mannkind Corporation | 1 | $12 |
| Novo Nordisk | 1 | $11 |
How this compares
$6,083 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $4,182 |
| Aripiprazole | 17 | $715 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 25 | $537 |
| Buprenorphine Hcl | 16 | $312 |
| Lamotrigine | 19 | $263 |
| Duloxetine Hcl | 17 | $260 |
| Methylphenidate Hcl | 13 | $254 |
| Quetiapine Fumarate | 13 | $249 |
| Clonazepam | 11 | $65 |
| Alprazolam | 28 | $62 |
| Sertraline Hcl | 13 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Almatica Pharma LLCSertraline Hcl | $14 | $5213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Fort Worth
- Andrew KimFort Worth$2M
- Diana GhelberFort Worth$1.9M
- Leslie SmithFort Worth$1.4M
- Alan PodawiltzFort Worth$409K
- Scott BartleyDallas$42.7M
- David BrownAustin$15.8M
- Rajinder ShiwachDesoto$15.4M
- Darin OkudaDallas$14.7M
- Jason MensahBeaumont$10.3M
- Michael DowningDallas$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.